irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Jean‐Christophe Pignon(Brigham and Women's Hospital), Sabina Signoretti(Brigham and Women's Hospital), Kathleen M. Mahoney(Beth Israel Deaconess Medical Center), Arlene H. Sharpe(Brigham and Women's Hospital), Catherine J. Wu(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Michael B. Atkins(Georgetown University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Jesse Novak(Brigham and Women's Hospital), Abdallah Flaifel(Brigham and Women's Hospital), Paul J. Catalano(Computational Physics (United States)), David A. Braun(Yale Cancer Center), Gordon J. Freeman(Dana-Farber Cancer Institute), Sachet A. Shukla(Broad Institute), F. Stephen Hodi(Harvard University), Opeyemi A. Jegede(Dana-Farber Cancer Institute), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Christine E. Horak(Bristol-Myers Squibb (United States)), David F. McDermott(Beth Israel Deaconess Medical Center), Yuko Ishii(Bristol-Myers Squibb (United States)), Jonian Grosha(Brigham and Women's Hospital)
Cited by 121
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k